Pharmacogenetics of acenocoumarol: CYP2C9 *2 and VKORC1 c.-1639G>A, 497C>G, 1173C>T, and 3730G>A variants influence drug dose in anticoagulated patients

Verde Rello, ZoraidaSantiago Dorrego, CatalinaValle Borrego, BeatrizFernández Santander, AnaBandrés Moya, FernandoCalvo, ElpidioRuiz, Jonatan R.Lucía Mulas, AlejandroGallego, Fe2013-11-272013-11-272009Verde-Rello, Z., Santiago-Dorrego, C., Valle-Borrego, B., Fernández-Santander, A., Bandrés, F., Calvo, E., ..., & Gómez-Gallego, F. (2009). Pharmacogenetics of acenocoumarol: CYP2C9* 2 and VKORC1 c.-1639G> A, 497C> G, 1173C> T, and 3730G> A variants influence drug dose in anticoagulated patients. Thromb Haemost,101, 591-593.03406245http://hdl.handle.net/11268/293engAnticoagulants/*PharmacokineticsAryl Hydrocarbon Hydroxylases/*GeneticsMixed Function Oxygenases/*GeneticsAnticoagulants/Administration & DosageFemaleHumansMaleMiddle AgedPolymorphism, GeneticRisk FactorsPharmacogenetics of acenocoumarol: CYP2C9 *2 and VKORC1 c.-1639G>A, 497C>G, 1173C>T, and 3730G>A variants influence drug dose in anticoagulated patientsjournal article10.1160/TH08-09-0578restricted accessFarmacología